UBS has reaffirmed a "buy" recommendation on Alcon Inc and designated the Swiss-headquartered eye-care company as its preferred large-cap pick, backing the call with an unchanged discounted cash flow-derived price target of CHF95. At the current share price of CHF63.06, UBS s target implies in excess of 50% upside.
The bank values Alcon at CHF31.1 billion in market capitalisation and projects a 12-month stock return of 51.1% versus UBS s assumed market return of 5.2%.
Near-term revenue momentum and analyst forecasts
UBS s analysts expect organic revenue growth of at least 7% in the first quarter, which would sit at the top end of Alcon management s full-year constant-currency guidance range of 5-7%.
For fiscal 2026 UBS models revenue of $11.31 billion, representing growth of 8.8% year-over-year, with adjusted EBIT of $2.36 billion. Diluted earnings per share are forecast at $3.46 for 2026, up from $3.07 in 2025 according to UBS s projections.
How product exposure supports guidance
UBS highlights that products representing 6% of group revenues account for around half of the company s guidance midpoint, and that calculation assumes no further acceleration in those products' exit rates. In UBS s view, that implies the remainder of the business only needs to grow in line with the market for management to hit the midpoint of its guidance.
Three catalysts identified beyond the Q1 earnings release
The brokerage outlines three specific catalysts that it expects to influence Alcon s trajectory after the upcoming first-quarter results, which are scheduled for May 6.
- PowerVision data readout - mid-2026: UBS points to a mid-2026 data readout for PowerVision, an accommodating and tunable implantable lens. The analysts estimate the product could push premium intraocular lens (IOL) penetration in the United States from approximately 20% toward the 30-40% ceiling that Alcon has cited, potentially lifting overall market growth by 1-3 percentage points. IOL sales currently constitute about 20% of Alcon s group revenues.
- Unity Dx launch - second half of 2026: Alcon plans to bring Unity Dx to market in the second half of 2026. Unity Dx is a diagnostic platform that combines at least three instruments into a single device. Management has estimated a $300 million market opportunity for the platform, which UBS interprets as the potential to double Alcon s diagnostics business. At present, Alcon holds roughly a 5% share of a $2.6 billion diagnostics market.
- AURN001 Phase 3 headline data - mid-2027: UBS notes that Alcon s majority-owned Aurion Biotech is expected to report Phase 3 headline data in mid-2027 for AURN001, a cell therapy targeting corneal endothelial disease. Management has guided for peak sales above $500 million. UBS further estimates the U.S. opportunity alone could be $1.5 billion, based on roughly 50,000 corneal transplant procedures performed annually in the United States and a Medicare cost near $30,000 per procedure.
Adjustments, valuation and balance-sheet metrics
Following fourth-quarter results and foreign exchange adjustments, UBS has lifted its 2026 adjusted net income estimate by 3%, and applies adjustments of 0-1% in subsequent years. The CHF95 DCF price target remains unchanged and is derived using a weighted average cost of capital of 7.5% and a terminal growth rate of 2.5%.
On UBS-adjusted diluted basis, Alcon is projected to trade at 23.4 times 2026 estimated P/E, falling to 19.6 times in 2027 and 16.8 times in 2028. Enterprise value to EBITDA is modelled at 15.4 times for 2026, decreasing to 13.5 times in 2027 and 11.9 times in 2028. Net debt to EBITDA is forecast at 1.3 times for 2026.
Bottom line
UBS s recommendation rests on a combination of above-guidance near-term organic growth expectations, a set of upcoming product and clinical catalysts, and valuation metrics that the bank deems supportive of upside to a CHF95 DCF-based target. The identified catalysts - the PowerVision readout, Unity Dx launch and Phase 3 results from Aurion Biotech - are central to UBS s upside case and to the bank s revenue and earnings projections through 2026.